ABVC BioPharma (NASDAQ:ABVC) Trading 4.7% Higher – Time to Buy?

ABVC BioPharma, Inc. (NASDAQ:ABVC) shares rose 4.7% during mid-day trading on Wednesday . The stock traded as high as $0.8960 and last traded at $0.8645. 138,162 shares traded hands during trading, an increase of 30% from the average daily volume of 106,374 shares. The stock had previously closed at $0.8254.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

ABVC BioPharma Stock Down 4.4%

The firm has a market capitalization of $25.48 million, a price-to-earnings ratio of -3.17 and a beta of 0.61. The company has a 50-day moving average price of $1.17 and a 200-day moving average price of $1.23.

ABVC BioPharma (NASDAQ:ABVC) last announced its earnings results on Wednesday, August 12th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.37.

Institutional Investors Weigh In On ABVC BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in ABVC BioPharma in the third quarter worth about $48,000. Millennium Management LLC acquired a new position in ABVC BioPharma during the 3rd quarter valued at about $60,000. Finally, Geode Capital Management LLC raised its position in shares of ABVC BioPharma by 5.8% during the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after buying an additional 6,017 shares in the last quarter. 11.38% of the stock is currently owned by institutional investors.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.